alendronate has been researched along with Becker Muscular Dystrophy in 5 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs." | 5.37 | [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]. ( Ballester Herrera, MJ; Carmona Vilchez, RM; Márquez de La Plata, MA; Medina Cano, E; Palomo Atance, E, 2011) |
| "Osteoporosis is a major problem in patients with Duchenne muscular dystrophy (DMD), due to glucocorticoid therapy and muscle weakness." | 1.56 | Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy. ( Hornung, L; Khoury, JC; Rutter, MM; Rybalsky, I; Shellenbarger, KC; Tian, C; Wong, BL, 2020) |
| "Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs." | 1.37 | [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]. ( Ballester Herrera, MJ; Carmona Vilchez, RM; Márquez de La Plata, MA; Medina Cano, E; Palomo Atance, E, 2011) |
| "In deflazacort-treated boys, alendronate had a positive effect on BMD z scores; the effect was greatest when given early in the course of disease." | 1.33 | Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy. ( Biggar, WD; Chase, CC; Fielding, LJ; Harris, VA; Hawker, GA; Ridout, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, C | 1 |
| Wong, BL | 1 |
| Hornung, L | 1 |
| Khoury, JC | 1 |
| Rybalsky, I | 1 |
| Shellenbarger, KC | 1 |
| Rutter, MM | 1 |
| Zheng, WB | 1 |
| Dai, Y | 1 |
| Hu, J | 1 |
| Zhao, DC | 1 |
| Wang, O | 1 |
| Jiang, Y | 1 |
| Xia, WB | 1 |
| Xing, XP | 1 |
| Li, M | 1 |
| Houston, C | 1 |
| Mathews, K | 1 |
| Shibli-Rahhal, A | 1 |
| Palomo Atance, E | 1 |
| Ballester Herrera, MJ | 1 |
| Márquez de La Plata, MA | 1 |
| Medina Cano, E | 1 |
| Carmona Vilchez, RM | 1 |
| Hawker, GA | 1 |
| Ridout, R | 1 |
| Harris, VA | 1 |
| Chase, CC | 1 |
| Fielding, LJ | 1 |
| Biggar, WD | 1 |
5 other studies available for alendronate and Becker Muscular Dystrophy
| Article | Year |
|---|---|
Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Chi | 2020 |
Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Child; Diphosphonates; Female; Humans; | 2020 |
Bone density and alendronate effects in Duchenne muscular dystrophy patients.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alendronate; Bone Density; Bone Density Conservation Agen | 2014 |
[Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
Topics: Alendronate; Bone Density Conservation Agents; Child; Humans; Muscular Dystrophy, Duchenne; Osteopor | 2011 |
Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
Topics: Alendronate; Bone and Bones; Bone Density; Child; Glucocorticoids; Humans; Male; Muscular Dystrophy, | 2005 |